New Delhi: Defense Research and Development Organization (DRDO) has given license to pharmaceutical company Mankind Pharma to manufacture and market oral 2-deoxy-D-glucose (2-DG), which is used for the treatment of COVID-19.
Mankind Pharma said in a statement that 2-DG was developed by the Defense Research and Development Establishment (DRDE), Gwalior.
The pharmaceutical firm said the clinical trial was conducted by DRDO’s laboratory, Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy’s Laboratories.
reading: Sanofi – GSK gets DCGI nod for Phase III trial of its COVID vaccine in India; All you need to know
Mankind Pharma will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh.
The Office of the Drugs Controller General of India (DCGI) had on May 1 allowed the emergency use of 2-DG for moderate to severe COVID-19 patients, PTI quoted Mankind Pharma as saying.
While the drug is found to help hospitalized coronavirus patients recover faster, it is also known to reduce supplemental oxygen dependence among Covid-19 patients, the company said.
read also: After Covid, Oxford scientists target HIV; Human trial of vaccine begins
Mankind Pharma further said, “Our objective behind this agreement is to ensure maximum access of this drug to eligible Indian patients suffering from the deadly pandemic.”
See below health equipment-
Calculate your body mass index (BMI)
.